May 28, 2024, 04:25
Arndt Vogel: A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Arndt Vogel shared on X:
“A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas, European Journal of Cancer.
- Stopped at IA due to futility.
- Comparable activity, safety manageable.
- Not good, but both are options in 2nd line.”
Additional information.
Source: Arndt Vogel/X
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School.
He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.
A. Bongiovanni
Arndt Vogel
B. Rudnas
C. Liverani
cancer
CAPTEM
D. Santini
European Journal of Cancer
F. Bergamo
F. Foca
F. Gelsomino
F. Pucci
F. Recine
F. Spada
FOLFIRI
G. Badalamenti
G. Di Meglio
Hannover Medical School
I. Lolli
L. Antonuzzo
M. Cives
M. Tebaldi
M.P. Brizzi
N. Ranallo
neuroendocrine carcinomas
O. Nanni
OncoDaily
Oncology
R. Berardi
R. Marconcini
S. Leo
S. Pusceddu
S. Severi
S. Tamberi
S. Vanni
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12